Ashley M.
About Ashley M.
Ashley M. serves as the Director of Corporate Engagement & Government Affairs at Catalyst Inc. and has a strong background in advocacy and fundraising, having raised $1.3 million for an advocacy program and secured government funding for health initiatives across Canada.
Work at Catalyst Inc.
Ashley M. serves as the Director of Corporate Engagement & Government Affairs at Catalyst Inc. since 2019. In this role, she focuses on enhancing corporate partnerships and engaging with government entities to advance organizational goals. Additionally, she has held the position of Director, Women on Board & Government Affairs, Canada at Catalyst Inc. since 2017. Her work involves promoting women's representation on boards and advocating for policies that support gender equality in leadership roles.
Education and Expertise
Ashley M. completed her Bachelor of Arts at St. Thomas University in Canada from 1997 to 2001. Her educational background provides a foundation for her extensive career in government affairs and corporate engagement. She has developed expertise in advocacy, fundraising, and policy negotiation, which she applies in her current roles and previous positions.
Background
Ashley M. has a diverse professional background in government relations and advocacy. She worked at the House of Commons as an Advisor from 2001 to 2008, where she gained significant experience in political processes. Following this, she held various roles in organizations focused on breast cancer advocacy, including Senior Government Relations & Policy Manager at the Canadian Breast Cancer Network and Senior Advocacy Manager at Rethink Breast Cancer.
Achievements
Ashley M. has demonstrated strong fundraising capabilities, raising $1.3 million to support an advocacy program. She successfully negotiated with the Ontario Minister of Health to establish an expert panel and committee aimed at reducing wait times for breast reconstruction, which was established in 2014. Additionally, she played a pivotal role in securing government funding for the implementation of Oncotype Dx across multiple Canadian provinces, including Alberta, British Columbia, and Nova Scotia.